Strategy in TECH...
On Tuesday, after the close of financial markets, Masimo Corporation (Nasdaq: MASI) announced its financial performance for the fourth quarter and full year of Fiscal 2024. Consolidated revenues grew a mere 2%, and the company booked a net loss of $304.9 million. And yet, investors were thrilled, driving up the value of shares of MASI stock by a double-digit percentage on the first trading day after the announcement.
What?!?!
Masimo Corporation’s (Nasdaq: MASI) Board of Directors announced late Tuesday afternoon that it has appointed Catherine “Katie” Syzman as the company’s new Chief Executive Officer (CEO) and as a director on the newly expanded board. Current Interim CEO Michelle Brennan will transition to a new role as Chairman of the Masimo Board. Finally, Lead Independent Director Quentin Koffey has been appointed Vice Chairman of the Board.
This announcement sets key pieces of the reconstituted management team in place, holding promise of a new era at the medical products company. All of the above changes take effect on February 12, 2025.
